Diyabetik Maküler Ödemde İntravitreal Bevacizumab ile Kombine Bevacizumab ve Maküler Fotokoagülasyon'un Karşılaştırılması

Abstract

Objective: To compare the efficacy of intravitreal bevacizumab with combined bevacizumab followed by sequential macular laser photocoagulation in the treatment of diabetic macular edema. Material and Methods: Thirty-one eyes injected with intravitreal bevacizumab and 30 eyes with combined therapy of bevacizumab injection and macular laser photocoagulation were included in this retrospective study. The main outcome measures were visual acuity, central macular thickness and the number of injections. Results: Each participant completed at least 6 months of follow-up. Baseline best-corrected visual acuity and central macular thickness values of the bevacizumab monotherapy group were similar to those of the combination group. In bevacizumab monotherapy group, baseline best-corrected visual acuity (0.91±0.65 logMAR) improved to 0.73±0.55 logMAR at 3 months and to 0.68±0.53 logMAR at 6 months of follow-up. Baseline central macular thickness decreased from 431.65 ±108.19 μm to 381.77±113.29 μm at 3 months and to 366.82±105.13 μm at 6 months. In the combination group, baseline best-corrected visual acuity improved from 0.84±0.63 logMAR to 0.55±0.48 logMAR at 3 months and to 0.41±0.46 log-MAR at 6 months, while baseline central macular thickness decreased from 400.77±119.05 μm to 287.10 ± 67.99 μm at 3 months and to 265.24±81.48 μm at 6 months following the treatment. Conclusion: Both treatment modalities were effective in improving visual acuity and reducing central macular thickness. Adding macular laser to intravitreal bevacizumab appeared to be superior to bevacizumab alone in eyes with diabetic macular edema.